ESPR Q4 2016 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q4 2016 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$29M

EPS (Diluted)

$-1.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$245M

Total Liabilities

$17M

Stockholders' Equity

$229M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$29M	-$13M	-121.3%
Net Income	-$29M	-$13M	-120.7%